Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Feb;14(2):92-6.
doi: 10.1007/BF02765777.

The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation

E C Ditkoff  1 , R Prosser, R C Zimmermann, S Lindheim, M V Sauer
Affiliations

The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation

E C Ditkoff et al. J Assist Reprod Genet. 1997 Feb.

Abstract

Purpose: Our goal was to determine if the addition of norethindrone acetate (NETA) to leuprolide acetate (LA) has an adverse effect on controlled ovarian stimulation (COH) during in vitro fertilization (IVF).

Methods: Forty-one consecutive patients undergoing COH and IVF were divided into two groups and evaluated. Group 1 consisted of 18 patients who did not become pregnant following two cycles (one of each protocol). Group 2 consisted of 23 patients who became clinically pregnant following one cycle from either protocol. The standard protocol consisted of LA (1 mg) injected subcutaneously from the first day of menses until day 8 or when ovarian suppression was evident, at which time the dose was halved and COH was initiated. The study protocol was identical except 10 mg of NETA was given orally with LA for the first 8 days. Ovarian stimulation was similar in each protocol.

Results: No adverse effect on ovarian stimulation was evident on the addition of NETA to LA. No differences were noted in days of stimulation, peak estradiol (E2) level attained, peak E2-to-oocyte ratio, dosage of exogenous gonadotropins, number of aspirated oocytes, fertilization rate, or oocyte and preembryo quality.

Conclusions: The addition of NETA does not attenuate COH in women undergoing IVF.

PubMed Disclaimer

References

    1. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet. 1984;2:1284–1285. doi: 10.1016/S0140-6736(84)92840-X. - DOI - PubMed
    1. Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, Cristol P, Viala JL. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril. 1987;47:639–643. - PubMed
    1. Yen SSC. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril. 1983;29:257–266. - PubMed
    1. Sampaio M, Serra V, Miro F, Calatayud C, Castellvi RM, Pellicer A. Development of ovarian cysts during gonadotropin-releasing hormone agonists (GnRHa), administration. Hum Reprod. 1991;6:194–197. - PubMed
    1. Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC, Rivier J, Yen SS, Lobo RA. Comparison of intermittent and continuous use of a gonadotropin releasing hormone antagonist (Nal-Glu) in in vitro fertilization: A preliminary report. Am J Obstet Gynecol. 1991;165:1790–1794. - PubMed

MeSH terms